The company has received the final approval from the United States
Food & Drug Administration (USFDA) for its abbreviated new drug
application (ANDA) for Deferasirox tablets in the strength of 180 mg,
Alembic Pharmaceuticals said in a BSE filing.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-generic-chronic-iron-overload-treatment-tablets/articleshow/76401337.cms
No comments:
Post a Comment